162 related articles for article (PubMed ID: 23789895)
21. Genotoxicity of poly(propylene imine) dendrimers.
Ziemba B; Matuszko G; Appelhans D; Voit B; Bryszewska M; Klajnert B
Biopolymers; 2012 Aug; 97(8):642-8. PubMed ID: 22605555
[TBL] [Abstract][Full Text] [Related]
22. Structural dependence of in vitro cytotoxicity, oxidative stress and uptake mechanisms of poly(propylene imine) dendritic nanoparticles.
Khalid H; Mukherjee SP; O'Neill L; Byrne HJ
J Appl Toxicol; 2016 Mar; 36(3):464-73. PubMed ID: 26671548
[TBL] [Abstract][Full Text] [Related]
23. Performance evaluation of PAMAM dendrimer based simvastatin formulations.
Kulhari H; Pooja D; Prajapati SK; Chauhan AS
Int J Pharm; 2011 Feb; 405(1-2):203-9. PubMed ID: 21145960
[TBL] [Abstract][Full Text] [Related]
24. Dendrimers for enhanced drug solubilization.
Svenson S; Chauhan AS
Nanomedicine (Lond); 2008 Oct; 3(5):679-702. PubMed ID: 18817470
[TBL] [Abstract][Full Text] [Related]
25. Poly(propylene imine) dendrimer caps on mesoporous silica nanoparticles for redox-responsive release: smaller is better.
Nadrah P; Porta F; Planinšek O; Kros A; Gaberšček M
Phys Chem Chem Phys; 2013 Jul; 15(26):10740-8. PubMed ID: 23689395
[TBL] [Abstract][Full Text] [Related]
26. Studying complexes between PPI dendrimers and Mant-ATP.
Szulc A; Appelhans D; Voit B; Bryszewska M; Klajnert B
J Fluoresc; 2013 Mar; 23(2):349-56. PubMed ID: 23306952
[TBL] [Abstract][Full Text] [Related]
27. Polyamidomine dendrimers: an excellent drug carrier for improving the solubility and bioavailability of puerarin.
Gu L; Wu Zh; Qi X; He H; Ma X; Chou X; Wen X; Zhang M; Jiao F
Pharm Dev Technol; 2013; 18(5):1051-7. PubMed ID: 22303809
[TBL] [Abstract][Full Text] [Related]
28. Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer.
Kesharwani P; Tekade RK; Jain NK
Biomaterials; 2014 Jul; 35(21):5539-48. PubMed ID: 24731713
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of polyamidoamine dendrimers as potential carriers for quercetin, a versatile flavonoid.
Madaan K; Lather V; Pandita D
Drug Deliv; 2016; 23(1):254-62. PubMed ID: 24845475
[TBL] [Abstract][Full Text] [Related]
30. Poly (amidoamine) dendrimer-mediated hybrid formulation for combination therapy of ramipril and hydrochlorothiazide.
Singh MK; Pooja D; Kulhari H; Jain SK; Sistla R; Chauhan AS
Eur J Pharm Sci; 2017 Jan; 96():84-92. PubMed ID: 27614111
[TBL] [Abstract][Full Text] [Related]
31. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro study.
Cheng Y; Qu H; Ma M; Xu Z; Xu P; Fang Y; Xu T
Eur J Med Chem; 2007 Jul; 42(7):1032-8. PubMed ID: 17336426
[TBL] [Abstract][Full Text] [Related]
32. Poly(amidoamine) dendrimers increase antifungal activity of clotrimazole.
Winnicka K; Sosnowska K; Wieczorek P; Sacha PT; Tryniszewska E
Biol Pharm Bull; 2011; 34(7):1129-33. PubMed ID: 21720026
[TBL] [Abstract][Full Text] [Related]
33. Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: considering their contrary potential as biocompatible entity and drug molecule in cancer.
Ziemba B; Franiak-Pietryga I; Pion M; Appelhans D; Muñoz-Fernández MÁ; Voit B; Bryszewska M; Klajnert-Maculewicz B
Int J Pharm; 2014 Jan; 461(1-2):391-402. PubMed ID: 24361266
[TBL] [Abstract][Full Text] [Related]
34. Study of the interactions of PAMAM G3-NH2 and G3-OH dendrimers with 5-fluorouracil in aqueous solutions.
Buczkowski A; Waliszewski D; Urbaniak P; Palecz B
Int J Pharm; 2016 May; 505(1-2):1-13. PubMed ID: 27039147
[TBL] [Abstract][Full Text] [Related]
35. Dendrimers as versatile platform in drug delivery applications.
Svenson S
Eur J Pharm Biopharm; 2009 Mar; 71(3):445-62. PubMed ID: 18976707
[TBL] [Abstract][Full Text] [Related]
36. Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate.
Kurmi BD; Gajbhiye V; Kayat J; Jain NK
J Pharm Sci; 2011 Jun; 100(6):2311-20. PubMed ID: 21491447
[TBL] [Abstract][Full Text] [Related]
37. The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI.
Franiak-Pietryga I; Ziółkowska E; Ziemba B; Appelhans D; Voit B; Szewczyk M; Góra-Tybor J; Robak T; Klajnert B; Bryszewska M
Mol Pharm; 2013 Jun; 10(6):2490-501. PubMed ID: 23641871
[TBL] [Abstract][Full Text] [Related]
38. Sugar-Modified Poly(propylene imine) Dendrimers Stimulate the NF-κB Pathway in a Myeloid Cell Line.
Jatczak-Pawlik I; Gorzkiewicz M; Studzian M; Appelhans D; Voit B; Pulaski L; Klajnert-Maculewicz B
Pharm Res; 2017 Jan; 34(1):136-147. PubMed ID: 27766462
[TBL] [Abstract][Full Text] [Related]
39. One platform comparison of solubilization potential of dendrimer with some solubilizing agents.
Jain S; Kesharwani P; Tekade RK; Jain NK
Drug Dev Ind Pharm; 2015 May; 41(5):722-7. PubMed ID: 24641446
[TBL] [Abstract][Full Text] [Related]
40. Impact of Dendrimer Terminal Group Chemistry on Blockage of the Anthrax Toxin Channel: A Single Molecule Study.
Yamini G; Kalu N; Nestorovich EM
Toxins (Basel); 2016 Nov; 8(11):. PubMed ID: 27854272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
